Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.55 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.55 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.45 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24579578 | 0.86 | GRM2 (0.53) | AGTR1AGTR2GRM2LMNAL3MBTL1 | |
| SCHEMBL1839002 | 0.81 | LMNA (0.52) | AGTR1AGTR2GRM2LMNAL3MBTL1 | |
| SCHEMBL15071657 | 0.80 | LMNA (0.55) | AGTR1AGTR2GRM2LMNAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL7837414 | 0.80 | LMNA (0.51) | AGTR1AGTR2GRM2LMNAL3MBTL1 | |
| SCHEMBL11957619 | 0.78 | SOS1 (0.58) | PPARG | |
| SCHEMBL31729500 | 0.77 | LMNA (0.68) | GRM2LMNAL3MBTL1GPR142 | |
| SCHEMBL11957613 | 0.75 | CYP19A1 (0.60) | GRM2BCAT2 | |
| SCHEMBL1844592 | 0.75 | LMNA (0.49) | AGTR1AGTR2PPARGLMNAL3MBTL1 | |
| SCHEMBL31270697 | 0.75 | LMNA (0.74) | LMNAL3MBTL1 | |
| SCHEMBL11113913 | 0.74 | LMNA (0.64) | GRM2LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236843-B2 | Anti inflammatory compounds | ELDER PHARMACEUTICALS LTD. (IN) | 2012-08-07 | — | — | US | disclosed |
| US-8236843-B2 | Anti inflammatory compounds | ELDER PHARMACEUTICALS LTD. (IN) | 2012-08-07 | — | — | US | disclosed |
| US-8236843-B2 | Anti inflammatory compounds | ELDER PHARMACEUTICALS LTD. (IN) | 2012-08-07 | — | — | US | disclosed |
| US-20110263543-A1 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2011-10-27 | — | — | US | disclosed |
| US-20110263543-A1 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2011-10-27 | — | — | US | disclosed |
| US-20110263543-A1 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2011-10-27 | — | — | US | disclosed |
| WO-2010029576-A2 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263543-A1 | ANTI INFLAMMATORY COMPOUNDS | IL1B, LITAF, IL6 | AGTR1 1702/4885AGTR2 1149/4885GRM2 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.